Harbinder Singh
Research Subjects
Research Interests
Harbinder Singh has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Sahil Sharma
Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
21 shared publications - Preet Mohinder Singh Bedi
Guru Nanak Dev University
16 shared publications Kavita Bhagat
Department of Pharmaceutical Sciences Guru Nanak Dev University Amritsar Punjab India
11 shared publications- Atamjit Singh
Department of Pharmaceutical Sciences Guru Nanak Dev University Amritsar Punjab India
10 shared publications - Harmandeep Kaur Gulati
School of Medical & Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India; Adarsh Vijendra Institute of Pharmaceutical Sciences, Gangoh, Saharanpur, Shobhit University, Uttar Pradesh, India
10 shared publications Jatinder Vir Singh
Guru Nanak Dev University
9 shared publications
Latest Publications
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1681-1691
Structure-Based Optimization of Triazole-Linked Sesamol Conjugates as Antifungal Agents Targeting CYP51 in Candida albicans
The increasing prevalence of azole-resistant Candida albicans due to extensive and irrational use of antifungal agents demands the development of new selective and effective antifungal agents. Here, we designed a series of triazole-linked sesamol-based conjugates using an integrated e-pharmacophore and molecular hybridization approach. Compounds were synthesized and evaluated for anti-Candida efficacy against a panel of pathogenic Candida strains. Among them, compound CH3 displayed the highest antifungal efficacy against Candida albicans (MIC = 1.9 μM and MFC = 3.9 μM). CH3 also showed biofilm eradication activity, and drug resistance was not observed in a 30 day resistance induction assay. CH3 was nontoxic and capable of rescuing larvae (G. mellonella) from the Candida-infected larvae model. With a favorable safety profile and desirable potency in both in vitro and in vivo, CH3 is a promising lead molecule for future drug development against Candida infections.
- 28 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1681-1691
Structure-Based Optimization of Triazole-Linked Sesamol Conjugates as Antifungal Agents Targeting CYP51 in Candida albicans
The increasing prevalence of azole-resistant Candida albicans due to extensive and irrational use of antifungal agents demands the development of new selective and effective antifungal agents. Here, we designed a series of triazole-linked sesamol-based conjugates using an integrated e-pharmacophore and molecular hybridization approach. Compounds were synthesized and evaluated for anti-Candida efficacy against a panel of pathogenic Candida strains. Among them, compound CH3 displayed the highest antifungal efficacy against Candida albicans (MIC = 1.9 μM and MFC = 3.9 μM). CH3 also showed biofilm eradication activity, and drug resistance was not observed in a 30 day resistance induction assay. CH3 was nontoxic and capable of rescuing larvae (G. mellonella) from the Candida-infected larvae model. With a favorable safety profile and desirable potency in both in vitro and in vivo, CH3 is a promising lead molecule for future drug development against Candida infections.
- 17 September 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (10) , 1986-1996
Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan–Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy
A novel series of triazole-tethered monoterpenoid-lignan hybrid molecules has been designed to target xanthine oxidase (XO), the enzyme responsible for hyperuricemia when it is up-regulated, resulting in gout and other metabolic disorders. Designed molecules were synthesized and initially evaluated for their XO inhibitory potential, and MT7 was most active (XO: IC50 = 0.263 ± 0.06 μM) with radical scavenging efficacy. MT7 showed higher cytotoxic potential against XO harboring cancer cells (MBDA-MB-231 breast cancer cells) than non-XO-harboring cells (A547 skin cancer cells), confirming intracellular XO inhibition. MT7 was nontoxic to mouse fibroblast cells (L929) and had favorable pharmacokinetic profiles. In vivo investigations in rodent-based animal models revealed the LD50 (300 mg/kg) value of MT7 and a dose-dependent reduction in serum uric acid. Overall, this suggests MT7 as an effective lead molecule for further investigations as a potential clinical candidate for the management of hyperuricemia via XO inhibition.
- 17 September 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (10) , 1986-1996
Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan–Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy
A novel series of triazole-tethered monoterpenoid-lignan hybrid molecules has been designed to target xanthine oxidase (XO), the enzyme responsible for hyperuricemia when it is up-regulated, resulting in gout and other metabolic disorders. Designed molecules were synthesized and initially evaluated for their XO inhibitory potential, and MT7 was most active (XO: IC50 = 0.263 ± 0.06 μM) with radical scavenging efficacy. MT7 showed higher cytotoxic potential against XO harboring cancer cells (MBDA-MB-231 breast cancer cells) than non-XO-harboring cells (A547 skin cancer cells), confirming intracellular XO inhibition. MT7 was nontoxic to mouse fibroblast cells (L929) and had favorable pharmacokinetic profiles. In vivo investigations in rodent-based animal models revealed the LD50 (300 mg/kg) value of MT7 and a dose-dependent reduction in serum uric acid. Overall, this suggests MT7 as an effective lead molecule for further investigations as a potential clinical candidate for the management of hyperuricemia via XO inhibition.
- Open Access
- 2 August 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 35
Various Approaches Employed to Enhance the Bioavailability of Antagonists Interfering with the HMGB1/RAGE Axis
High-mobility group box 1 (HMGB1) is a nuclear protein that can interact with a transmembrane cell surface receptor for advanced glycation end products (RAGEs) and mediates the inflammatory pathways that lead to various pathological conditions like cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders. Blocking the HMGB1/RAGE axis using various small synthetic or natural molecules has been proven to be an effective therapeutic approach to treating these inflammatory conditions. However, the low water solubility of these pharmacoactive molecules limits their clinical use. Pharmaceutically active molecules with low solubility and bioavailability in vivo convey a higher risk of failure for drug development and drug innovation. The pharmacokinetic and pharmacodynamics parameters of these compounds are majorly affected by their solubility. Enhancement of the bioavailability and solubility of drugs is a significant challenge in the area of pharmaceutical formulations. This review mainly describes various technologies utilized to improve the bioavailability of synthetic or natural molecules which have been particularly used in various inflammatory conditions acting specifically through the HMGB1/RAGE pathway.
- 2 August 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 35
Open AccessVarious Approaches Employed to Enhance the Bioavailability of Antagonists Interfering with the HMGB1/RAGE Axis
High-mobility group box 1 (HMGB1) is a nuclear protein that can interact with a transmembrane cell surface receptor for advanced glycation end products (RAGEs) and mediates the inflammatory pathways that lead to various pathological conditions like cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders. Blocking the HMGB1/RAGE axis using various small synthetic or natural molecules has been proven to be an effective therapeutic approach to treating these inflammatory conditions. However, the low water solubility of these pharmacoactive molecules limits their clinical use. Pharmaceutically active molecules with low solubility and bioavailability in vivo convey a higher risk of failure for drug development and drug innovation. The pharmacokinetic and pharmacodynamics parameters of these compounds are majorly affected by their solubility. Enhancement of the bioavailability and solubility of drugs is a significant challenge in the area of pharmaceutical formulations. This review mainly describes various technologies utilized to improve the bioavailability of synthetic or natural molecules which have been particularly used in various inflammatory conditions acting specifically through the HMGB1/RAGE pathway.
- 2 February 2023
- Published by Springer Nature
- p. 217-250
Recent Development of Quinoline Derivatives as Anticancer Agents: 2015–2022
- 2 February 2023
- Published by Springer Nature
- p. 217-250
Recent Development of Quinoline Derivatives as Anticancer Agents: 2015–2022
- Open Access
Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
High mobility group box 1 (HMGB1) is a nuclear protein that can interact with a receptor for advanced glycation end-products (RAGE; a multi-ligand immunoglobulin receptor) and mediates the inflammatory pathways that lead to various pathological conditions, such as cancer, diabetes, neurodegenerative disorders, and cardiovascular diseases. Blocking the HMGB1/RAGE axis could be an effective therapeutic approach to treat these inflammatory conditions, which has been successfully employed by various research groups recently. In this article, we critically review the structural insights and functional mechanism of HMGB1 and RAGE to mediate inflammatory processes. More importantly, current perspectives of recent therapeutic approaches utilized to inhibit the communication between HMGB1 and RAGE using small molecules are also summarized along with their clinical progression to treat various inflammatory disorders. Encouraging results are reported by investigators focusing on HMGB1/RAGE signaling leading to the identification of compounds that could be useful in further clinical studies. We highlight the current gaps in our knowledge and future directions for the therapeutic potential of targeting key molecules in HMGB1/RAGE signaling in the pathophysiology of inflammatory diseases.
Open AccessTherapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
High mobility group box 1 (HMGB1) is a nuclear protein that can interact with a receptor for advanced glycation end-products (RAGE; a multi-ligand immunoglobulin receptor) and mediates the inflammatory pathways that lead to various pathological conditions, such as cancer, diabetes, neurodegenerative disorders, and cardiovascular diseases. Blocking the HMGB1/RAGE axis could be an effective therapeutic approach to treat these inflammatory conditions, which has been successfully employed by various research groups recently. In this article, we critically review the structural insights and functional mechanism of HMGB1 and RAGE to mediate inflammatory processes. More importantly, current perspectives of recent therapeutic approaches utilized to inhibit the communication between HMGB1 and RAGE using small molecules are also summarized along with their clinical progression to treat various inflammatory disorders. Encouraging results are reported by investigators focusing on HMGB1/RAGE signaling leading to the identification of compounds that could be useful in further clinical studies. We highlight the current gaps in our knowledge and future directions for the therapeutic potential of targeting key molecules in HMGB1/RAGE signaling in the pathophysiology of inflammatory diseases.
- Open Access
- 10 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 12012
Targeting the Crosstalk of Immune Response and Vascular Smooth Muscle Cells Phenotype Switch for Arteriovenous Fistula Maturation
Plaque formation, thrombosis, and embolism are the underlying causes of acute cardiovascular events such as myocardial infarction and stroke while early thrombosis and stenosis are common pathologies for the maturation failure of arteriovenous fistula (AVF). Chronic inflammation is a common underlying pathogenesis mediated by innate and adaptive immune response involving infiltration of immune cells and secretion of pro- and anti-inflammatory cytokines. Impaired immune cell infiltration and change in vascular smooth muscle cell (VSMC) phenotype play a crucial role in the underlying pathophysiology. However, the change in the phenotype of VSMCs in a microenvironment of immune cell infiltration and increased secretion of cytokines have not been investigated. Since change in VSMC phenotype regulates vessel remodeling after intimal injury, in this study, we investigated the effect of macrophages and pro-inflammatory cytokines, IL-6, IL-1β, and TNF-α, on the change in VSMC phenotype under in vitro conditions. We also investigated the expression of the markers of VSMC phenotypes in arteries with atherosclerotic plaques and VSMCs isolated from control arteries. We found that the inhibition of cytokine downstream signaling may mitigate the effect of cytokines on the change in VSMCs phenotype. The results of this study support that regulating or targeting immune cell infiltration and function might be a therapeutic strategy to mitigate the effects of chronic inflammation to attenuate plaque formation, early thrombosis, and stenosis, and thus enhance AVF maturation.
- 10 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 12012
Open AccessTargeting the Crosstalk of Immune Response and Vascular Smooth Muscle Cells Phenotype Switch for Arteriovenous Fistula Maturation
Plaque formation, thrombosis, and embolism are the underlying causes of acute cardiovascular events such as myocardial infarction and stroke while early thrombosis and stenosis are common pathologies for the maturation failure of arteriovenous fistula (AVF). Chronic inflammation is a common underlying pathogenesis mediated by innate and adaptive immune response involving infiltration of immune cells and secretion of pro- and anti-inflammatory cytokines. Impaired immune cell infiltration and change in vascular smooth muscle cell (VSMC) phenotype play a crucial role in the underlying pathophysiology. However, the change in the phenotype of VSMCs in a microenvironment of immune cell infiltration and increased secretion of cytokines have not been investigated. Since change in VSMC phenotype regulates vessel remodeling after intimal injury, in this study, we investigated the effect of macrophages and pro-inflammatory cytokines, IL-6, IL-1β, and TNF-α, on the change in VSMC phenotype under in vitro conditions. We also investigated the expression of the markers of VSMC phenotypes in arteries with atherosclerotic plaques and VSMCs isolated from control arteries. We found that the inhibition of cytokine downstream signaling may mitigate the effect of cytokines on the change in VSMCs phenotype. The results of this study support that regulating or targeting immune cell infiltration and function might be a therapeutic strategy to mitigate the effects of chronic inflammation to attenuate plaque formation, early thrombosis, and stenosis, and thus enhance AVF maturation.
- 1 September 2022
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 14 (19) , 1403-1416
Recent Advancements in the Discovery of Cereblon-Based Protease-Targeted Chimeras With Potential for Therapeutic Intervention
Protease-targeted chimeras (PROTACs) have been employed as a novel therapeutic approach, utilizing the ubiquitin-proteasome system for targeted protein degradation. PROTACs are heterobifunctional m...
- 1 September 2022
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 14 (19) , 1403-1416
Recent Advancements in the Discovery of Cereblon-Based Protease-Targeted Chimeras With Potential for Therapeutic Intervention
Protease-targeted chimeras (PROTACs) have been employed as a novel therapeutic approach, utilizing the ubiquitin-proteasome system for targeted protein degradation. PROTACs are heterobifunctional m...
- Open Access
Trifluoromethylated Quinolone-Hydantoin Hybrids: Synthesis and Antibacterial Evaluation
A series of new trifluoromethyl-substituted quinolones and hydantoin hybrids has been synthesized and evaluated against Gram-positive bacterium (Staphylococcus aureus MTCC 96) and Gram-negative bacteria (Pseudomonas aeruginosa MTCC 441, Klebsiella pneumonia MTCC 109, and Escherichia coli MTCC 442). Compound 19c, having the 6-propene group on the quinolone ring, showed similar activity to a standard drug (chloramphenicol) by exhibiting MIC values of 50 µg/mL against S. aureus and P. aeruginosa. Physicochemical properties of compound 19c were also determined, which were in line with Lipinski’s rule of five, suggesting the suitability of compound 19c in biological systems. Various types of binding interactions of 19c within the active site of DNA gyrase of S. aureus were also streamlined by molecular docking studies, suggesting its capability to block the catalytic process of the DNA gyrase, which could be the possible reason for its antibacterial potential.
Open AccessTrifluoromethylated Quinolone-Hydantoin Hybrids: Synthesis and Antibacterial Evaluation
A series of new trifluoromethyl-substituted quinolones and hydantoin hybrids has been synthesized and evaluated against Gram-positive bacterium (Staphylococcus aureus MTCC 96) and Gram-negative bacteria (Pseudomonas aeruginosa MTCC 441, Klebsiella pneumonia MTCC 109, and Escherichia coli MTCC 442). Compound 19c, having the 6-propene group on the quinolone ring, showed similar activity to a standard drug (chloramphenicol) by exhibiting MIC values of 50 µg/mL against S. aureus and P. aeruginosa. Physicochemical properties of compound 19c were also determined, which were in line with Lipinski’s rule of five, suggesting the suitability of compound 19c in biological systems. Various types of binding interactions of 19c within the active site of DNA gyrase of S. aureus were also streamlined by molecular docking studies, suggesting its capability to block the catalytic process of the DNA gyrase, which could be the possible reason for its antibacterial potential.
- Open Access
- 4 July 2022
- Published by Wiley in Drug Development Research
- Vol. 83 (6) , 1257-1269
Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors
Receptor for advanced glycation end products (RAGE) is a 45 kDa transmembrane receptor of immunoglobulin family that can bind to various endogenous and exogenous ligands and initiate the inflammatory downstream signaling pathways. RAGE is involved in various disorders including cardiovascular and neurodegenerative diseases, cancer, and diabetes. This review summarizes the structural features of RAGE and its various isoforms along with their pathological effects. Mainly, the article emphasized on the translational significance of antagonizing the interactions of RAGE with its ligands using small molecules reported in the last 5 years and discusses future approaches that could be employed to block the interactions in the treatment of chronic inflammatory ailments. The RAGE inhibitors described in this article could prove as a powerful approach in the management of immune‐inflammatory diseases. A critical review of the literature suggests that there is a dire need to dive deeper into the molecular mechanism of action to resolve critical issues that must be addressed to understand RAGE‐targeting therapy and long‐term blockade of RAGE in human diseases.
- 4 July 2022
- Published by Wiley in Drug Development Research
- Vol. 83 (6) , 1257-1269
Open AccessTherapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors
Receptor for advanced glycation end products (RAGE) is a 45 kDa transmembrane receptor of immunoglobulin family that can bind to various endogenous and exogenous ligands and initiate the inflammatory downstream signaling pathways. RAGE is involved in various disorders including cardiovascular and neurodegenerative diseases, cancer, and diabetes. This review summarizes the structural features of RAGE and its various isoforms along with their pathological effects. Mainly, the article emphasized on the translational significance of antagonizing the interactions of RAGE with its ligands using small molecules reported in the last 5 years and discusses future approaches that could be employed to block the interactions in the treatment of chronic inflammatory ailments. The RAGE inhibitors described in this article could prove as a powerful approach in the management of immune‐inflammatory diseases. A critical review of the literature suggests that there is a dire need to dive deeper into the molecular mechanism of action to resolve critical issues that must be addressed to understand RAGE‐targeting therapy and long‐term blockade of RAGE in human diseases.
- 30 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (9) , 8663-8672
LPS and oxLDL-induced S100A12 and RAGE expression in carotid arteries of atherosclerotic Yucatan microswine
Background S100A12, also known as Calgranulin C, is a ligand for the receptor for advanced glycation end products (RAGE) and plays key roles in cardiovascular and other inflammatory diseases. Interactions between S100A12 and RAGE initiate downstream signaling activating extracellular signal-regulated kinases (ERK1/2), mitogen activated protein kinases (MAPK), and transcription factor NF-κB. This increases the expression of pro-inflammatory cytokines to induce the inflammatory response. S100A12, and RAGE play a critical role in the development and progression of atherosclerosis. There is a well-known relationship between the bacterial endotoxin lipopolysaccharide (LPS) and the lipid antigens oxidized low-density lipoprotein (oxLDL) in driving the immune response in atherosclerosis. Methods and results Our study aimed to compare the potential of LPS and oxLDL in regulating the expression of S100A12 and RAGE in atherosclerosis. The expression of these proteins was assessed in the harvested carotid arteries from LPS- and oxLDL-treated atherosclerotic Yucatan microswine. Tissues were collected from five different treatment groups: (i) angioplasty alone, (ii) LPS alone, (iii) oxLDL alone, (iv) angioplasty with LPS, and (v) angioplasty with oxLDL. Immunohistochemical findings revealed that angioplasty with LPS induced higher expression of S100A12 and RAGE compared to other treatment groups. The results were further corroborated by testing their gene expression through qPCR in cultured vascular smooth muscle cells (VSMCs) isolated from control carotid arteries and LPS- and oxLDL-treated arteries. Conclusions The results of this study suggest that LPS induces the expression of S100A12 and RAGE more than oxLDL in atherosclerotic artery and both S100A12 and RAGE could be therapeutic targets.
- 30 June 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (9) , 8663-8672
LPS and oxLDL-induced S100A12 and RAGE expression in carotid arteries of atherosclerotic Yucatan microswine
Background S100A12, also known as Calgranulin C, is a ligand for the receptor for advanced glycation end products (RAGE) and plays key roles in cardiovascular and other inflammatory diseases. Interactions between S100A12 and RAGE initiate downstream signaling activating extracellular signal-regulated kinases (ERK1/2), mitogen activated protein kinases (MAPK), and transcription factor NF-κB. This increases the expression of pro-inflammatory cytokines to induce the inflammatory response. S100A12, and RAGE play a critical role in the development and progression of atherosclerosis. There is a well-known relationship between the bacterial endotoxin lipopolysaccharide (LPS) and the lipid antigens oxidized low-density lipoprotein (oxLDL) in driving the immune response in atherosclerosis. Methods and results Our study aimed to compare the potential of LPS and oxLDL in regulating the expression of S100A12 and RAGE in atherosclerosis. The expression of these proteins was assessed in the harvested carotid arteries from LPS- and oxLDL-treated atherosclerotic Yucatan microswine. Tissues were collected from five different treatment groups: (i) angioplasty alone, (ii) LPS alone, (iii) oxLDL alone, (iv) angioplasty with LPS, and (v) angioplasty with oxLDL. Immunohistochemical findings revealed that angioplasty with LPS induced higher expression of S100A12 and RAGE compared to other treatment groups. The results were further corroborated by testing their gene expression through qPCR in cultured vascular smooth muscle cells (VSMCs) isolated from control carotid arteries and LPS- and oxLDL-treated arteries. Conclusions The results of this study suggest that LPS induces the expression of S100A12 and RAGE more than oxLDL in atherosclerotic artery and both S100A12 and RAGE could be therapeutic targets.